Skip to main content
Key Specialties
Cardiology Diabetology Endocrinology Gastroenterology Geriatrics and Gerontology Gynecology and Obstetrics Hematology Infectious Disease Internal Medicine Nephrology Neurology Oncology Pediatrics Respiratory Medicine Rheumatology Surgery
Congress Coverage
2024 ACC Congress 2023 ESMO Congress 2023 EASD Congress 2023 ERS Congress 2023 ESC Congress
Clinical Collections
Advances in Alzheimer’s

At a glance: The STEP trials

A round-up of the STEP phase 3 clinical trials evaluating semaglutide for weight loss in people with overweight or obesity.
ADVANCED SEARCH
Log in
Top
Inflammation Research
Published in: Inflammation Research 10/2014

Open Access 01-10-2014 | Review

Inflammation and vitamin D: the infection connection

Authors: Meg Mangin, Rebecca Sinha, Kelly Fincher

Published in: Inflammation Research | Issue 10/2014

Login to get access

Abstract

Introduction

Inflammation is believed to be a contributing factor to many chronic diseases. The influence of vitamin D deficiency on inflammation is being explored but studies have not demonstrated a causative effect.

Methods

Low serum 25(OH)D is also found in healthy persons exposed to adequate sunlight. Despite increased vitamin D supplementation inflammatory diseases are increasing. The current method of determining vitamin D status may be at fault. The level of 25(OH)D does not always reflect the level of 1,25(OH)2D. Assessment of both metabolites often reveals elevated 1,25(OH)2D, indicating abnormal vitamin D endocrine function.

Findings

This article reviews vitamin D's influence on the immune system, examines the myths regarding vitamin D photosynthesis, discusses ways to accurately assess vitamin D status, describes the risks of supplementation, explains the effect of persistent infection on vitamin D metabolism and presents a novel immunotherapy which provides evidence of an infection connection to inflammation.

Conclusion

Some authorities now believe that low 25(OH)D is a consequence of chronic inflammation rather than the cause. Research points to a bacterial etiology pathogenesis for an inflammatory disease process which results in high 1,25(OH)2D and low 25(OH)D. Immunotherapy, directed at eradicating persistent intracellular pathogens, corrects dysregulated vitamin D metabolism and resolves inflammatory symptoms.
Literature
1.
Cheng T, Chimeh C, Lu Z, et al. Factors that influence the cutaneous synthesis and dietary sources of vitamin D. Arch Bio Biophs. 2007;460(2):213–7.
2.
Jones G. Pharmacokinetics of vitamin D toxicity. Am J Clin Nutr. 2008;88(2):582–6.
3.
Holick M, Schnoes H, Deluca H, Suda T, Cousins R. Isolation and identification of 1,25-dihydroxycholecalciferol. A metabolite of vitamin D active in intestine. Biochem. 1971;10(14):2799–804.
4.
Adams J, Hewison M. Extrarenal expression of the 25-hydroxyvitamin d-1-hydroxylase. Arch Biochem Biophys. 2012;523(1):95–102.PubMedPubMedCentral
5.
Haddad J, Vitamin D. Binding protein (Gc-globulin): multiple tasks. J Steroid Biochem Mol Biol. 1996;53(1–6):579–82.
6.
Sutton A, MacDonald P. Vitamin D: more than a “bone-a-fide” hormone. Mol Endocrinol. 2003;17(5):777–91.PubMed
7.
White JH. Vitamin D signaling, infectious diseases, and regulation of innate immunity. Infect Immun. 2008;76(9):3837–43.PubMedPubMedCentral
8.
Lai Y, Gallo RL. AMPed up immunity: how antimicrobial peptides have multiple roles in immune defense. Trends Immunol. 2009;30(3):131–41.PubMedPubMedCentral
9.
Wang T, Nestel F, Bourdeau V, et al. Cutting edge: 1,25-dihydroxyvitamin D3 is a direct inducer of antimicrobial peptide gene expression. J Immunol. 2004;173(5):2909–12.PubMed
10.
Hayes C, Nashold F, Spach K, Pedersen L. The immunological functions of the vitamin D endocrine system. Cell Mol Biol (Noisy-le-grand). 2003;49(2):277–300.
11.
Topilski I, Flaishon L, Naveh Y, Harmelin A, Levo Y, Shachar I. The anti-inflammatory effects of 1,25-dihydroxyvitamin D3 on Th2 cells in vivo are due in part to the control of integrin-mediated T lymphocyte homing. Eur J Immunol. 2004;34(4):1068–76.PubMed
12.
Maxmen A. Nutrition advice: the vitamin D-lemma. Nature. 2011;475(7354):23–5.PubMed
13.
Autier P, Gandini S. Vitamin D supplementation and total mortality: a meta-analysis of randomized controlled trials. Arch Intern Med. 2007;167(16):1730–7.PubMed
14.
15.
Holick MF, Binkley NC, Bischoff-Ferrari HA, et al. Guidelines for preventing and treating vitamin D deficiency and insufficiency revisited. J Clin Endocrinol Metab. 2012;97(4):1153–8.PubMed
16.
Ross AC, Taylor CL, Yaktine AL, Del Valle HB. Dietary reference intakes for calcium and vitamin D. Washington: National Academy of Sciences; 2010. 0-309-16394-3.
17.
18.
19.
20.
Snellman G, Melhus H, Gedeborg R, et al. Seasonal genetic influence on serum 25-hydroxyvitamin D levels: a twin study. PLoS One. 2009;4(11):e7747.PubMedPubMedCentral
21.
Bogh MK, Schmedes AV, Philipsen PA, Thieden E, Wulf HC. Vitamin D production depends on ultraviolet-B dose but not on dose rate: a randomized controlled trial. Exp Dermatol. 2011;20(1):14–8.PubMed
22.
Bogh MK, Schmedes AV, Philipsen PA, Theiden E, Wulf HC. Vitamin D production after UVB exposure depends on baseline vitamin D and total cholesterol but not on skin pigmentation. J Invest Dermatol. 2010;130(2):546–53.PubMed
23.
Matsuoka LY, Worstman J, Haddad JG, Kolm P, Hollis BW. Racial pigmentation and the cutaneous synthesis of vitamin D. Arch Dermatol. 1991;127(4):536–8.PubMed
24.
Matsuoka LY, Wortsman J, Chen TC, Holick MF. Compensation for the interracial variance in the cutaneous synthesis of vitamin D. J Lab Clin Med. 1995;126(5):452–7.PubMed
25.
Villa M, Kelsey J, Chen J, Marcus R. Skin Pigmentation does not affect vitamin D status in community-dwelling Mexican–American women. J Bone Miner Res. 1994;9(Suppl 1):S418.
26.
Matsuoka LY, Wortsman J, Dannenberg MJ, Holis BW, Lu Z, Holick MF. Clothing prevents ultraviolet-B radiation-dependent photosynthesis of vitamin D3. J Clin Endocrinol Metab. 1992;75(4):1099–103.PubMed
27.
28.
Matsuoka LY, Ide L, MacLaughlin JA, Holick MF. Sunscreens suppress cutaneous vitamin D3 synthesis. J Clin Endocrinol Metab. 1987;64(6):1165–8.PubMed
29.
Diehl JW, Chiu MW. Effects of ambient sunlight and photoprotection on vitamin D status. Dermatol Ther. 2010;23(1):48–60.PubMed
30.
Youl PH, Janda M, Kimlin M. Vitamin D and sun protection: the impact of mixed public health messages in Australia. Int J Cancer. 2009;124(8):1963–70.PubMed
31.
Global Solar UV Index: A Practical Guide. Geneva, Switzerland: World Health Organization; 2002. ISBN 9241590076.
32.
MacLaughlin J, Holick MF. Aging decreases the capacity of human skin to produce vitamin D3. J Clin Invest. 1985;76(4):1536–8.PubMedPubMedCentral
33.
Chuck A, Todd J, Diffey B. Subliminal ultraviolet-B irradiation for the prevention of vitamin D deficiency in the elderly: a feasibility study. Photodermatol Photoimmunol Photomed. 2001;17(4):168–71.PubMed
34.
Chel VG, Ooms ME, Popp-Snijders C, et al. Ultraviolet irradiation corrects vitamin D deficiency and suppresses secondary hyperparathyroidism in the elderly. J Bone Miner Res. 1998;13(8):1238–42.PubMed
35.
Webb AR, Kline L, Holick MF. Influence of season and latitude on the cutaneous synthesis of vitamin D3: exposure to winter sunlight in Boston and Edmonton will not promote vitamin D3 synthesis in human skin. Clin Endocrinol Metab. 1988;67(2):373–8.
36.
Kimlin MG, Olds WJ, Moore MR. Location and vitamin D synthesis: is the hypothesis validated by geophysical data? J Photochem Photobiol B. 2007;86(3):234–9.PubMed
37.
Lubin D, Jensen EH, Gies HP. Global surface ultraviolet radiation climatology from TOMS and ERBE data. J Geo Res. 1998;103(D20):26061–91.
38.
39.
Al-Othman A, Al-Musharaf S, Al-Daghri NM, et al. Tea and coffee consumption in relation to vitamin D and calcium levels in Saudi adolescents. Nutr J. 2012;11:56.PubMedPubMedCentral
40.
Willis KS, Smith DT, Broughton KS, Larson-Meyer DE. Vitamin D status and biomarkers of inflammation in runners. Open Access J Sports Med. 2012;2012(3):35–42.
41.
Binkley N, Novotny R, Krueger D, et al. Low vitamin D status despite abundant sun exposure. J Clin Endocrinol Metab. 2007;92(6):2130–5.PubMed
42.
Blaney GP, Albert PJ, Proal AD. Vitamin D metabolites as clinical markers in autoimmune and chronic disease. Ann NY Acad Sci. 2009;1173:384–90.PubMed
43.
Brot C, Jorgensen NR, Sorensen OH. The influence of smoking on vitamin D status and calcium metabolism. Eur J Clin Nutr. 1999;53(12):920–6.PubMed
44.
Tiosano D, Hochberg Z. Hypophosphatemia: the common denominator of all rickets. J Bone Miner Metab. 2009;27(4):392–401.PubMed
45.
46.
Lerch C, Meissner T. Interventions for the prevention of nutritional rickets in term born children. Cochrane Database Syst Rev. 2007;4:CD006164.
47.
Pettifor JM, Ross P, Wang J, Moodley G, Couper-Smith J. Rickets in children of rural origin in South Africa: is low dietary calcium a factor? J Pediatr. 1978;92(2):320–4.PubMed
48.
Pettifor JM. Nutritional rickets: deficiency of vitamin D, calcium, or both? Am J Clin Nutr. 2004;80(6 Suppl):1725S–9S.PubMed
49.
Reid IR, Bolland MJ, Grey A. Effects of vitamin D supplements on bone mineral density: a systematic review and meta-analysis. Lancet. 2013;383:146–55.PubMed
50.
Boden SD, Kaplan FS. Calcium homeostasis. Orthop Clin North Am. 1990;21(1):31–42.PubMed
51.
52.
Abreu MT, Kantorovich V, Vasiliauskas EA, et al. Measurement of vitamin D levels in inflammatory bowel disease patients reveals a subset of Crohn’s disease patients with elevated 1,25-dihydroxyvitamin D and low bone mineral density. Gut. 2004;53(8):1129–36.PubMedPubMedCentral
53.
Brot C, Jørgensen N, Madsen OR, Jensen LB, Sørensen OH. Relationships between bone mineral density, serum vitamin D metabolites and calcium:phosphorus intake in healthy perimenopausal women. J Intern Med. 1999;245(5):509–16.PubMed
54.
Ishizuka S, Kurihara N, Miura D, et al. Vitamin D antagonist, TEI-9647, inhibits osteoclast formation induced by 1alpha,25-dihydroxyvitamin D3 from pagetic bone marrow cells. J Steroid Biochem Mol Biol. 2004;89–90(1–5):331–4.PubMed
55.
Vanderschueren D, Pye SR, O’Neill TW, et al. Active vitamin D (1,25-dihydroxyvitamin D) and bone health in middle-aged and elderly men: the European Male Aging Study (EMAS). J Clin Endocrinol Metab. 2013;98(3):995–1005.PubMed
56.
Chung M, Lee J, Terasawa T, Lau J, Trikalinos TA. Vitamin D with or without calcium supplementation for prevention of cancer and fractures: an updated meta-analysis for the US. Preventive Services Task Force. Ann Intern Med. 2011;155(12):827–38.PubMed
57.
Whayne TF Jr. Vitamin D: popular cardiovascular supplement but benefit must be evaluated. Int J Angiol. 2011;20(2):63–72.PubMedPubMedCentral
58.
Shelby J. Needs great, evidence lacking for people with multiple chronic conditions. Scribd. Apr 2013. Accessed 7 May 2013.
59.
60.
61.
Bjelakovic G, Gluud LL, Nikolova D, et al. Vitamin D supplementation for prevention of mortality in adults. Cochrane Database Syst Rev. 2011;(7):CD007470.
62.
Holick MF. Environmental factors that influence the cutaneous production of vitamin D. Am J Clin Nutr. 1995;61(3 Suppl):638S–45S.PubMed
63.
Vieth R. Vitamin D supplementation, 25-hydroxyvitamin D concentrations, and safety. Am J Clin Nutr. 1999;69(5):842–56.PubMed
64.
Noordam R, de Craen AJ, Pedram P, et al. Levels of 25-hydroxyvitamin D in familial longevity: the Leiden Longevity Study. CMAJ. 2012;184(18):E963–8.PubMedPubMedCentral
65.
Autier P, Boniol M, Pizot C, Mullie P. Vitamin D: chasing a myth? Vitamin D status and ill health: a systematic review. Lancet Diabetes Endocrinol. 2013.
66.
Bolland MJ, Grey A, Gamble GD, Reid IR. The effect of vitamin D supplementation on skeletal, vascular, or cancer outcomes: a trial sequential meta-analysis. Lancet Diabetes Endocrinol. 2014;4(2):307–20.PubMed
67.
Ross AC, Manson JE, Abrams SA, et al. The 2011 report on dietary reference intakes for calcium and vitamin D from the institute of medicine: what clinicians need to know. J Clin Endocrinol Metab. 2011;96(1):53–8.PubMedPubMedCentral
68.
Holick MF, Chen TC. Vitamin D deficiency: a worldwide problem with health consequences. Am J Clin Nutr. 2008;87:1080S–6S.PubMed
69.
Albert PJ, Proal AD, Marshall TG. Vitamin D the alternative hypothesis. Autoimmun Rev. 2009;8(8):639–44.PubMed
70.
Madoff S, editor. The Bacterial L-forms. 1st ed. USA: Marcel Dekker Inc; 1986.
71.
Allan EJ, Hoischen C, Gumpert J. Bacterial L-forms. Adv Appl Microbiol. 2009;68:1–39.PubMed
72.
Boya P. Lysosomal function and dysfunction: mechanism and disease. Antioxid Redox Signal. 2010;17(5):766–74.
73.
74.
O’Connor SM, Taylor CE, Hughes JM. Emerging infectious determinants of chronic diseases. Emerg Infect Dis. 2006;12(7):1051–7.PubMedPubMedCentral
75.
Domingue GJ. Demystifying pleomorphic forms in persistence and expression of disease: are they bacteria, and is peptidoglycan the solution? Discov Med. 2010;10(52):234–46.PubMed
76.
77.
Rolhion N, Darfeuille-Michaud A. Adherent-invasive Escherichia coli in inflammatory bowel disease. Inflamm Bowel Dis. 2007;13(10):1277–83.PubMed
78.
Onwuamaegbu ME, Belcher RA, Soare C. Cell wall-deficient bacteria as a cause of infections: a review of the clinical significance. J Int Med Res. 2005;33(1):1–20.PubMed
79.
Verway M, Behr MA, White JH. VitaminD NOD2, autophay and Crohn’s disease. Expert Rev Clin Immunol. 2010;6(4):505–8.PubMed
80.
Pirofski L, Casadevall A. Q and A what is a pathogen? A question that begs the point. BMC Biol. 2012;12:6.
81.
Hof H. Opportunistic intracellular bacteria and immunity. Antibiotic treatment of infections with intracellular bacteria. USA: Springer; 2002.
82.
Fuller E, Elmer C, Nattress F, Horne G, Cook P, Fawcett T. Beta-lactam resistance in Staphylococcus aureus cells that do not require a cell wall for integrity. Antimicrob Agents Chemother. 2005;49(12):5075–80.PubMedPubMedCentral
83.
Wróblewska J, Janicka G, Gospodarek E, Szymankiewicz M. L-forms of Staphylococcus epidermidis induced by penicillin. Pol J Microbiol. 2006;55(3):243–4.PubMed
84.
Garssen J, Vandebriel RJ, De Gruijl FR, et al. UVB exposure-induced systemic modulation of Th1- and Th2-mediated immune responses. Immunology. 1999;97(3):506–14.PubMedPubMedCentral
85.
Riminton DS, Hartung HP, Reddel SW. Managing the risks of immunosuppression. Curr Opin Neurol. 2011;24(3):217–23.PubMed
86.
Wall S, Kunze ZM, Saboor S, et al. Identification of spheroplast-like agents isolated from tissues of patients with Crohn’s disease and control tissues by polymerase chain reaction. J Clin Microbiol. 1993;31(5):1241–5.PubMedPubMedCentral
87.
Negi M, Takemura T, Guzman J, et al. Localization of propionibacterium acnes in granulomas supports a possible etiologic link between sarcoidosis and the bacterium. Mod Pathol. 2012;25(9):1284–97.PubMedPubMedCentral
88.
Astrauskiene D, Bernotiene E. New insights into bacterial persistence in reactive arthritis. Clin Exp Rheumatol. 2007;25(3):470–9.PubMed
89.
90.
Kozarov E. Bacterial invasion of vascular cell types: vascular infectology and atherogenesis. Future Cardiol. 2012;8(1):123–38.PubMedPubMedCentral
91.
Khan N, Gowthaman U, Pahari S, Agrewala JN. Manipulation of costimulatory molecules by intracellular pathogens: veni, vidi, vici! PLoS Pathog. 2012;8(6):e1002676.PubMedPubMedCentral
92.
Hajishengallis G, Lambris JD. Microbial manipulation of receptor crosstalk in innate immunity. Nat Rev Immunol. 2011;11(33):187–200.PubMedPubMedCentral
93.
Dörr T, Vulić M, Lewis K. Ciprofloxacin causes persister formation by inducing the TisB toxin in Escherichia coli. PLoS Biol. 2010;8(2):e1000317.PubMedPubMedCentral
94.
Fuks JM, Arrighi RB, Weidner JM, et al. GABAergic signaling is linked to a hypermigratory phenotype in dendritic cells infected by Toxoplasma gondii. PLoS Pathog. 2012;8(12):e1003051.PubMedPubMedCentral
95.
Smillie CS, Smith MB, Friedman J, Cordero OX, David LA, Alm EJ. Ecology drives a global network of gene exchange connecting the human microbiome. Nature. 2011;480(7376):241–4.PubMed
96.
Riley DR, Sieber KB, Robinson KM, et al. Bacteria–human somatic cell lateral gene transfer is enriched in cancer samples. PLOS Comput Biol. 2013;9(6):e1003107.PubMedPubMedCentral
97.
Helaine S, Cheverton AM, Watson KG, Faure LM, Matthews SA, Holden DW. Internalization of Salmonella by macrophages induces formation of nonreplicating persisters. Science. 2014;343(6167):204–208. Available at http://​www.​sciencemag.​org. Accessed 21 Jan 2014.
98.
Eishi Y. Etiologic aspect of sarcoidosis as an allergic endogenous infection caused by Propionibacterium acnes. Biomed Res Int. 2013;2013:935289.PubMedPubMedCentral
99.
Wang KX, Chen L. Helicobacter pylori L-form and patients with chronic gastritis. World J Gastroenterol. 2004;10(9):1306–9.PubMed
100.
Chen Y, Liu W, Sun T, et al. 1,25-Dihydroxyvitamin D promotes negative feedback regulation of TLR signaling via targeting MicroRNA-155-SOCS1 in macrophages. J Immunol. 2013;190(7):3687–95.PubMedPubMedCentral
101.
Nauciel C. Immune defenses against intracellular bacterial infection. In: Paradise LJ, Friedman H, Bendinelli M, editors. Opportunistic intracellular bacteria and immunity. New York: Kluwer Academic; 2002.
102.
Liu PT, Stenger S, Li H, et al. Toll-like receptor triggering of a vitamin D-mediated human antimicrobial response. Science. 2006;311(5768):1770–3.PubMed
103.
Alexander C, Rietschel ET. Bacterial lipopolysaccharides and innate immunity. J Endotoxin Res. 2001;7(3):167–202.PubMed
104.
105.
Oswald-Richter KA, Beachboard DC, Seeley EH, et al. Dual analysis for mycobacteria and propionibacteria in sarcoidosis BAL. J Clin Immunol. 2012;32(5):1129–40.PubMedPubMedCentral
106.
Labro M. Interference of antibacterial agents with phagocyte functions: immunomodulation or “immuno-fairy tales”? Clin Microbiol Rev. 2000;13(4):615–50.PubMedPubMedCentral
107.
Giongo A, Gano KA, Crabb DB, et al. Toward defining the autoimmune microbiome for type 1 diabetes. ISME J. 2011;5(1):82–91.PubMedPubMedCentral
108.
109.
Smith G. Angiotensin and systems thinking: wrapping your mind around the big picture. Ochsner J Spring. 2013;13(1):11–25.
110.
Woolard MD, Frelinger JA. Outsmarting the host: bacteria modulating the immune response. Immunol Res. 2008;41(3):188–202.PubMed
111.
Dermine JF, Desjardins M. Survival of intracellular pathogens within macrophages. Protoplasma. 1999;210(1–2):11–24.
112.
Xu Y, Xie J, Li Y, et al. Using a cDNA microarray to study cellular gene expression altered by Mycobacterium tuberculosis. Chin Med J (Engl). 2003;116(7):1070–3.
113.
Liu PT, Wheelwright M, Teles R, et al. MicroRNA-21 targets the vitamin D-dependent antimicrobial pathway in leprosy. Nat Med. 2012;18(2):267–73.PubMedPubMedCentral
114.
Coughlan CA, Chotirmall SH, Renwick J, et al. The effect of Aspergillus fumigatus infection on vitamin D receptor expression in cystic fibrosis. Am J Respir Crit Care Med. 2012;186(10):999–1007.PubMed
115.
Yenamandra SP, Lundin A, Arulampalam V, et al. Expression profile of nuclear receptors upon Epstein—Barr virus induced B cell transformation. Exp Oncol. 2009;31(2):92–6.PubMed
116.
Haug CJ, Aukrust P, Haug E, Mørkrid L, Müller F, Frøland SS. Severe deficiency of 1,25-dihydroxyvitamin D3 in human immunodeficiency virus infection: association with immunological hyperactivity and only minor changes in calcium homeostasis. J Clin Endocrinol Metab. 1998;83(11):3832–8.PubMed
117.
Yoshizawa T, Handa Y, Uematsu Y, et al. Mice lacking the vitamin D receptor exhibit impaired bone formation, uterine hypoplasia and growth retardation after weaning. Nat Genet. 1997;16(4):391–6.PubMed
118.
Sadeghi K, Wessner B, Laggner U, et al. Vitamin D3 down-regulates monocyte TLR expression and triggers. Eur J Immunol. 2006;36(2):361–70.PubMed
119.
Barna BP, Culver DA, Kanchwala A, et al. Alveolar macrophage cathelicidin deficiency in severe sarcoidosis. J Innate Immun. 2012;4(5–6):569–78.PubMedPubMedCentral
120.
Mawer EB, Hayes ME, Still PE, et al. Evidence for nonrenal synthesis of 1,25-dihydroxyvitamin D in patients with inflammatory arthritis. J Bone Miner Res. 1991;6(7):733–9.PubMed
121.
Wang TT, Dabbas B, Laperriere EG, et al. Direct and indirect induction by 1,25-dihydroxyvitamin D3 of the NOD2/CARD15-defensin beta2 innate immune pathway defective in Crohn disease. J Biol Chem. 2010;285(4):2227–31.PubMedPubMedCentral
122.
Lemire J. 1,25-Dihydroxyvitamin D3—a hormone with immunomodulatory properties. Z Rheumatol. 2000;59(Suppl 1):24–7.PubMed
123.
Deb DK, Chen Y, Zhang Z, et al. 1,25-Dihydroxyvitamin D3 suppresses high glucose-induced angiotensinogen expression in kidney cells by blocking the NF-{kappa}B pathway. 296(5):F1212–8.
124.
Mouy R, Fischer A, Vilmer E, Seger R, Griscelli C. Incidence, severity, and prevention of infections in chronic granulomatous disease. J Pediatr. 1989;114(1):555–60.PubMed
125.
126.
Domingue G, Turner B, Schlegel JU. Cell-wall deficient bacterial variants in kidney tissue. Detection by immunofluorescence. Urology. 1974;3(3):288–92.PubMed
127.
Pleister A, Eckels DD. Cryptic infection and autoimmunity. Autoimmun Rev. 2003;2(3):126–32.PubMed
128.
Chan TD, Wood K, Hermes JR, et al. Elimination of germinal-center-derived self-reactive B cells is governed by the location and concentration of self-antigen. Immunity. 2012;37(5):893–904.PubMed
129.
Blander JM, Torchinsky MB, Campisi L. Revisiting the old link between infection and autoimmune disease with commensals and T helper 17 cells. Immunol Res. 2012;54(1–3):50–68.PubMed
130.
Christen U, Hintermann E, Holdener M, von Herrath MG. Viral triggers for autoimmunity: is the ‘glass of molecular mimicry’ half full or half empty? J Autoimmun. 2010;34(1):38–44.PubMedPubMedCentral
131.
Proal AD, Albert PJ, Marshall TG. Autoimmune disease and the human metagenome. In: Nelson KE, editor. Metagenomics of the human body. 1st ed. USA: Springer; 2011.
132.
Berlin T, Zandman-Goddard G, Blank M, et al. Autoantibodies in nonautoimmune individuals during infections. Ann NY Acad Sci. 2007;1108:584–93.PubMed
133.
Molina V, Shoenfeld Y. Infection, vaccines and other environmental triggers of autoimmunity. Autoimmunity. 2005;38(3):235–45.PubMed
134.
Griffin MD, Xing N, Kumar R. Vitamin D and its analogs as regulators of immune activation and antigen presentation. Annu Rev Nutr. 2003;23:117–45.PubMed
135.
Zhang Y, Leung DY, Richers BN, et al. Vitamin D inhibits monocyte/macrophage proinflammatory cytokine production by targeting MAPK phosphatase-1. J Immunol. 2012;188(5):2127–35.PubMedPubMedCentral
136.
Böhm M, Luger TA, Schneider M, Schwarz T, Kuhn A. New insight into immunosuppression and treatment of autoimmune diseases. Clin Exp Rheumatol. 2006;24(1 Suppl 40):S67–71.PubMed
137.
Arnson Y, Amital H, Shoenfeld Y. Vitamin D and autoimmunity: new aetiological and therapeutic considerations. Ann Rheum Dis. 2007;66(9):1137–42.PubMedPubMedCentral
138.
Kim HM, Chung MJ, Chung JB. Remission and relapse of autoimmune pancreatitis: focusing on corticosteroid treatment. Pancreas. 2010;39(5):555–60.PubMed
139.
Collins FS. Reengineering translational science: the time is right. Sci Transl Med. 2011;3(90):9017.
140.
Norman A. From vitamin D to hormone D: fundamentals of the vitamin D endocrine system essential for good health. Am J Clin Nutr. 2008;88(2):491S–9S.PubMed
141.
Rasmussen SB, Reinert LS, Paludan SR. Innate recognition of intracellular pathogens: detection and activation of the first line of defense. APMIS. 2009;117(5–6):323–37.PubMed
142.
Dusso AS, Kamimura S, Gallieni M, et al. gamma-Interferon-induced resistance to 1,25-(OH)2D3 in human monocytes and macrophages: a mechanism for the hypercalcemia of various granulomatoses. J Clin Endocrinol Metab. 1997;82(7):2222–32.PubMed
143.
Edfeldt K, Liu PT, Chun R, et al. T-cell cytokines differentially control human monocyte antimicrobial responses by regulating vitamin D metabolism. Proc Natl Acad Sci USA. 2010;107(52):22593–8.PubMedPubMedCentral
144.
Lambert PW, Stern PH, Avioli RC, et al. Evidence for extrarenal production of 1 alpha,25-dihydroxyvitamin D in man. J Clin Invest. 1982;69(3):722–5.PubMedPubMedCentral
145.
Reichrath J. Vitamin D and the skin: an ancient friend, revisited. Exp Dermatol. 2007;16(7):618–25.PubMed
146.
Bikle DD. Vitamin D and immune function: understanding common pathways. Curr Osteoporos Rep. 2009;7(2):58–63.PubMed
147.
Jones G, Prosser DE, Kaufman M. 25-Hydroxyvitamin D-24-hydroxylase (CYP24A1): Its important role in the degradation of vitamin D. Arch Biochem Biophys. 2012;523(1):9–18.PubMed
148.
Xu Y, Hashizume T, Shuhart MC, et al. Intestinal and hepatic CYP3A4 catalyze hydroxylation of 1alpha,25-dihydroxyvitamin D(3): implications for drug-induced osteomalacia. Mol Pharmacol. 2006;69(1):56–65.PubMed
149.
Bell NH, Shaw S, Turner RT. Evidence that 1,25-dihydroxyvitamin D3 inhibits the hepatic production of 25-hydroxyvitamin D in man. J Clin Invest. 1984;74(4):1540–4.PubMedPubMedCentral
150.
Waldron JL, Ashby HL, Cornes MP, et al. Vitamin D: a negative acute phase reactant. J Clin Pathol. 2013 (Epub ahead of print).
151.
Ferder M, Inserra F, Manucha W, Ferder L. The world pandemic of Vitamin D deficit could possibly be explained by cellular inflammatory response activity induced by the renin angiotensin system. Am J Physiol Cell Physiol. 2013 (Epub ahead of print).
152.
Akbaraly TN, Hamer M, Ferrie JE, et al. Chronic inflammation as a determinant of future aging phenotypes. CMAJ. 2013 (Epub ahead of print).
153.
Phillips CM, Perry IJ. Does inflammation determine metabolic health status in obese and nonobese adults? J Clin Endocrinol Metab. 2013;98(10):E1610–9.PubMed
154.
Strathmann FG, Laha TJ, Hoofnagle AN. Quantification of 1α,25 dihydroxy vitamin D by immunoextraction and liquid chromatography–tandem mass spectrometry. Clin Chem. 2011;57(9):1279–85.PubMedPubMedCentral
155.
Hollis B. Detection of vitamin D and its major metabolites. In: Feldman D, Pike JW, Glorieux F, editors. vitamin D. San Diego: Elsevier Academic; 2005.
156.
Perez T. Bacteria induced vitamin D receptor dysfunction in autoimmune disease; theoretical and practical implication for interpretation of serum vitamin D metabolite levels. Paper presented at: 6th International Congress on Autoimmunity, 2006; Porto, Portugal.
157.
158.
Durup DJHCJSPHALB. A reverse J-shaped association of all-cause mortality with serum 25-hydroxyvitamin D in general practice: the CopD study. J Clin Endocrinol Metab. 2012;97(8):2644–52.PubMed
159.
Liu PT, Schenk M, Walker VP, et al. Convergence of IL-1beta and VDR activation pathways in human TLR2/1-induced antimicrobial responses. PLoS One. 2009;4(6):e5810.PubMedPubMedCentral
160.
Carlberg C, Molnar F. Detailed molecular understanding of agonistic and antagonistic vitamin D receptor ligands. Curr Top Med Chem. 2006;6(12):1243–53.PubMed
161.
Haussler M, Haussler C, Bartik L, et al. Vitamin D receptor: molecular signaling and actions of nutritional ligands in disease prevention. Nutr Rev. 2008;66(10 Suppl 2):98–112.
162.
Ishizawa M, Matsunawa M, Adachi R, et al. Lithocholic acid derivatives act as selective vitamin D receptor modulators without inducing hypercalcemia. J Lipid Res. 2008;49(4):763–72.PubMed
163.
Marshall TG, Lee RE, Marshall FE. Common angiotensin receptor blockers may directly modulate the immune system via VDR, PPAR and CCR2b. Theor Biol Med Model. 2006;3:1.PubMedPubMedCentral
164.
Waterhouse JC, Marshall TG, Fenter B, Mangin M, Blaney G. High levels of active 1,25-dihydroxyvitamin D despite low levels of the 25-hydroxyvitamin D precursor-implications of dysregulated vitamin D for diagnosis and treatment of chronic disease. In: Stolzt VD, editor. Vitamin D: New Research. New York: Nova Science Publishers; 2006.
165.
Arao T, Okada Y, Mori H, Nishida K, Tanaka Y. Antihypertensive and metabolic effects of high-dose olmesartan and telmisartan in type 2 diabetes patients with hypertension. Endocr J. 2013; (Epub ahead of print).
166.
Fliser D, Buchholz K, Haller H. Antiinflammatory effects of angiotensin II subtype 1 receptor blockade in hypertensive patients with microinflammation. Circulation. 2004;110(9):1103–7.PubMed
167.
Platten M, Youssef S, Hur EM, et al. Blocking angiotensin-converting enzyme induces potent regulatory T cells and modulates TH1- and TH17-mediated autoimmunity. Proc Natl Acad Sci USA. 2009;106(35):14948–53.PubMedPubMedCentral
168.
Izu Y, Mizoguchi F, Kawamata A, et al. Angiotensin II type 2 receptor blockade increases bone mass. J Biol Chem. 2009;284(8):4857–64.PubMed
169.
Shimuru H, Nakagami H, Osako MK, et al. Angiotensin II accelerates osteoporosis by activating osteoclasts. FASEB J. 2008;22(7):2465–75.
170.
Li YC, Kong J, Wei M, Chen ZF, Liu SQ, Cao LP. 1,25-Dihydroxyvitamin D(3) is a negative endocrine regulator of the renin-angiotensin system. J Clin Invest. 2002;110(2):229–38.PubMedPubMedCentral
171.
Suzuki Y, Ruiz-Ortega M, Lorenzo O, Ruperez M, Esteban V, Egido J. Inflammation and angiotensin II. Int J Biochem Cell Biol. 2003;35(6):881–900.PubMed
172.
Herxheimer K, Martin H. So-called Herxheimer reaction. Arch Derm Syphilol. 1926;13(1):115–7.
173.
Sonawane A, Santos JC, Mishra BB, et al. Cathelicidin is involved in the intracellular killing of mycobacteria in macrophages. Cell Microbiol. 2011;13(10):1601–17.PubMed
174.
Nickel D, Busch M, Mayer D, Hagemann B, Knoll V, Stenger S. Hypoxia triggers the expression of human beta defensin 2 and antimicrobial activity against Mycobacterium tuberculosis in human macrophages. J Immunol. 2012;188(8):4001–7.PubMed
175.
Hurley JC. Antibiotic-induced release of endotoxin. A therapeutic paradox. Drug Saf. Mar 1995;12(3):183–95.
176.
Schwocho LR, Masonson HN. Pharmacokinetics of CS-866, a new angiotensin II receptor blocker, in healthy subjects. J Clin Pharmacol. 2001;41(5):515–27.PubMed
177.
Ferrario C. Effect of angiotensin receptor blockade on endothelial function: focus on olmesartan medoxomil. Vasc Health Risk Manag. 2009;5(1):301–14.PubMedPubMedCentral
178.
Takizawa S, Dan T, Uesugi T, et al. A sartan derivative with a very low angiotensin II receptor affinity ameliorates ischemic cerebral damage. J Cereb Blood Flow Metab. 2009;29(10):1665–72.PubMed
179.
Proal AD, Albert PJ, Marshall TG, Blaney GP, Lindseth LA. Immunostimulation in the treatment for chronic fatigue syndrome/myalgic encephalomyelitis. Immunol Res. 2013;56:398–412.PubMed
180.
Hof H. Antibiotic treatment of infections with intracellular bacteria. In: Paradise LJ, Friedman H, Bendinelli M, editors. Opportunistic intracellular bacteria and immunity. New York: Kluwer Academic; 2002.
181.
Waterhouse JC, Perez TH, Albert PJ. Reversing bacteria-induced vitamin D receptor dysfunction is key to autoimmune disease. Ann NY Acad Sci. 2009;1173:757–65.PubMed
182.
Mangin M. Monitoring recovery from autoimmune disease with an interactive, internet-based clinical trial based on a molecular model of chronic disease. Paper presented at: 6th International Congress on Autoimmunity, 2008; Porto, Portugal.
183.
Kongsbak M, Levring TB, Geisler C, von Essen MR. The vitamin D receptor and T cell function. Front Immunol. 2013;4:148.PubMedPubMedCentral
Metadata
Title
Inflammation and vitamin D: the infection connection
Authors
Meg Mangin
Rebecca Sinha
Kelly Fincher
Publication date
01-10-2014
Publisher
Springer Basel
Published in
Inflammation Research / Issue 10/2014
Print ISSN: 1023-3830
Electronic ISSN: 1420-908X
DOI
https://doi.org/10.1007/s00011-014-0755-z

Other articles of this Issue 10/2014

Inflammation Research 10/2014 Go to the issue

Original Research Paper

NLRP3 inflammasome activation and interleukin-1β release in macrophages require calcium but are independent of calcium-activated NADPH oxidases

Original Research Paper

Docosahexanoic acid antagonizes TNF-α-induced necroptosis by attenuating oxidative stress, ceramide production, lysosomal dysfunction, and autophagic features

Original Research Paper

Albumin and glycated albumin activate KIM-1 release in tubular epithelial cells through distinct kinetics and mechanisms

Short Communication

Sorcin antibody as a possible predictive factor in conversion from radiologically isolated syndrome to multiple sclerosis: a preliminary study

Original Research Paper

Complement protein C1q promotes macrophage anti-inflammatory M2-like polarization during the clearance of atherogenic lipoproteins

Original Research Paper

Curcumin inhibits monocyte chemoattractant protein-1 expression and enhances cholesterol efflux by suppressing the c-Jun N-terminal kinase pathway in macrophage
Obesity Clinical Trial Summary

At a glance: The STEP trials

Read more

A round-up of the STEP phase 3 clinical trials evaluating semaglutide for weight loss in people with overweight or obesity.

Developed by: Springer Medicine

Highlights from the ACC 2024 Congress

Year in Review: Pediatric cardiology

Pediatric Cardiology Video

Watch Dr. Anne Marie Valente present the last year's highlights in pediatric and congenital heart disease in the official ACC.24 Year in Review session.

Year in Review: Pulmonary vascular disease

Cardiopulmonary Comorbidity Video

The last year's highlights in pulmonary vascular disease are presented by Dr. Jane Leopold in this official video from ACC.24.

Year in Review: Valvular heart disease

Valvular Heart Disease Video

Watch Prof. William Zoghbi present the last year's highlights in valvular heart disease from the official ACC.24 Year in Review session.

Year in Review: Heart failure and cardiomyopathies

Heart Failure Video

Watch this official video from ACC.24. Dr. Biykem Bozkurt discuss last year's major advances in heart failure and cardiomyopathies.

ACC 2024 Congress Coverage

Year in Review: Heart failure and cardiomyopathies

Heart Failure Video

Watch this official video from ACC.24. Dr. Biykem Bozkurt discuss last year's major advances in heart failure and cardiomyopathies.

Watch now

Semaglutide benefits people with type 2 diabetes and obesity-related heart failure

16-04-2024 Type 2 Diabetes News

Incentivised to exercise

11-04-2024 Lifestyle Modifications News

New intervention for STEMI-related cardiogenic shock

10-04-2024 Myocardial Infarction News

» View more highlights on the ACC 2024 congress hub page

Image Credits